Promising new combo aims to improve leukemia treatment

NCT ID NCT06773936

First seen Jan 11, 2026 · Last updated May 07, 2026 · Updated 15 times

Summary

This study tests whether adding the drug asciminib to usual treatment (dasatinib, prednisone, and blinatumomab) works better for people newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). About 55 adults will take part. The main goal is to see if the cancer's genetic marker drops to very low levels by day 85.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Baptist Memorial Health Care

    Memphis, Tennessee, 38120, United States

  • Cleveland Clinic Foundation

    Cleveland, Ohio, 44195, United States

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Northwell Health/Center for Advanced Medicine

    Lake Success, New York, 11042, United States

  • UC Irvine Medical Center

    Orange, California, 92868, United States

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania, 15232, United States

  • University of Cincinnati Cancer Ctr-UC Medical Ctr

    Cincinnati, Ohio, 45267, United States

  • University of Rochester Medical Center

    Rochester, New York, 14642, United States

Conditions

Explore the condition pages connected to this study.